Don't buy JAGSNPHARM now, it is underperforming the market
18 Nov, 20197 min read
JAGSNPHARM delivered massive losses today. On a longer term basis, investors in JAGSONPAL PHARMACEUTICALS made +0.11% per day. Monday's performance of -2.07% was a underperformance compared to it's daily average.
Want to improve your Portfolio's performance?
Spotalpha's Portfolio optimizer is all you need to improve your returns and reduce your risk.
Optimize Portfolio NOW
Read analysis
Symbol
Price
{{retType}}
|
Tr.
{{detail.symbol}}
{{detail.close}}
{{detail.priceChange}}
{{detail.pctChange}}%
{{detail.name}}
{{detail.trend}}
Share with friends 
